Reports from University Hospital Highlight Recent Findings in Drug Delivery Systems (Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel)
By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting out of Brest, France, by NewsRx editors, research stated, "Recently we reported for the first time a new type of nanocapsules consisting of an oily core and a polymer shell made of a polyglutamic acid-polyethylene glycol (PEG-PGA) grafted copolymer with a 24% w/w PEG content. The goal of the work presented here has been to develop a new version of these nanocapsules, in which the shell is made of a di-block PEG-PGA copolymer with a 57% w/w PEG content and to evaluate their potential for improving the biodistribution and pharmacokinetics of the anticancer drug docetaxel (DCX)."
Our news journalists obtained a quote from the research from University Hospital, "A comparative analysis of the biodistribution of fluorescently labeled PGA-PEG nanocapsules versus PGA nanocapsules or a control nanoemulsion (containing the same oil than the nanocapsules) showed that the nanocapsules, and in particular PEGylated nanocapsules, have significantly higher half-life, MRT (Mean Residence Time) and AUC (Area under the Curve) than the nanoemulsion. On a separate set of experiments, PGA-PEG nanocapsules were loaded with DCX and their antitumor efficacy was evaluated in a xenograft U87MG glioma mouse model. The results showed that the survival rate for mice treated with DCX-loaded nanocapsules was significantly increased over the control Taxotere, while the antitumoral effect of both formulations was comparable (60% tumor growth inhibition with respect to the untreated mice)."
According to the news editors, the research concluded: "These results highlight the potential use of these novel nanocapsules as a new drug delivery platform in cancer therapy."
For more information on this research see: Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel. European Journal of Pharmaceutics and Biopharmaceutics, 2014;87(1):47-54. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)
Our news journalists report that additional information may be obtained by contacting G. Lollo, CHRU Brest, Brest, France. Additional authors for this research include G.R. Rivera-Rodriguez, J. Bejaud, T. Montier, C. Passirani, J.P. Benoit, M. Garcia-Fuentes, M.J. Alonso and D. Torres (see also Drugs and Therapies).
Keywords for this news article include: Brest, France, Europe, Drug Delivery Systems, Drugs and Therapies, Emerging Technologies, Nanocapsules, Nanotechnology, Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC